[Effective long-term treatment of primary hyperlipoproteinemias with bezafibrate].

Abstract

Bezafibrate, a new hypolipidemic agent, was evaluated in a single blind, placebo-controlled study lasting 14 months to 3 years in 40 patients with primary hyperlipoproteinemia of various types (23 patients with type II, 15 with type IV and 2 with type V). Bezafibrate in a dose of 200 mg 3 times daily reduced total serum cholesterol by an average of 17% (p less than 0.001) in hyperlipoproteinemia type II and by 24% (p less than 0.001) in type IV or V, lowered serum triglycerides by 31% (p less than 0.001) in hyperlipoproteinemia type II and by 58% (p less than 0.001) in type IV or V, while high-density-lipoprotein-cholesterol was increased by 17% (p less than 0.001) in type II and by 36% (p less than 0.001) in type IV or V. The few side effects encountered were only mild and transient. These findings show that bezafibrate affords safe and effective long-term treatment of patients with hyperlipoproteinemia.

• Authors: H Schiffl, P Weidmann, C Fragiacomo, G Noseda, C Bachmann
• Journal: Schweizerische medizinische Wochenschrift (Schweiz Med Wochenschr) Vol. 115 Issue 26 Pg. 907-11 (Jun 29 1985) ISSN: 0036-7672 [Print] Switzerland
• Vernacular Title: Wirksame Langzeitbehandlung primärer Hyperlipoproteinämien mit Bezafibrat.
• PMID: 3927481 (Publication Type: Clinical Trial, Controlled Clinical Trial, English Abstract, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Cholesterol, HDL
• Placebos
• Triglycerides
• Cholesterol
• Creatinine
• Creatine Kinase
• Alkaline Phosphatase
• Bezafibrate

Topics

• Adult
• Aged
• Alkaline Phosphatase (metabolism)
• Bezafibrate (therapeutic use)
• Cholesterol (blood)
• Cholesterol, HDL (blood)
• Clinical Trials as Topic
• Creatine Kinase (metabolism)
• Creatinine (blood)
• Female
• Humans
• Hyperlipoproteinemia Type II (drug therapy)
• Hyperlipoproteinemia Type IV (drug therapy)
• Hyperlipoproteinemia Type V (drug therapy)
• Hyperlipoproteinemias (blood, drug therapy)
• Long-Term Care
• Male
• Middle Aged
• Placebos
• Triglycerides (blood)